

Xeracalm A.D

Effectiveness of lipid-replenishing balm on skin dryness induced by anti-cancer treatments



3
countries

319
patients

59% Women
41% Men

Study objectives

Assess the efficacy and tolerability of XeraCalm A.D lipid balm on patients with skin dryness induced by one or more oncological treatments.



2 medical consultations
spaced one-month apart

FIRST-LINE TREATMENT

IN ASSOCIATION

EAU THERMALE
Avène
LABORATOIRE DERMATOLOGIQUE



XERACALM A.D

XERACALM A.D ON SKIN DRYNESS INDUCED BY ONCOLOGICAL TREATMENTS¹

EFFICACY

Significant decrease in skin dryness severity

-62.7 %

TOLERABILITY

Tolerability is "very good" or "good" for

97.2 %
of patients

QUALITY OF LIFE

Improvement of the quality of life (DLQI* score) by

56.6 %

*DLQI: Dermatology Life Quality Index.

1. Observational study no. RV4429A 2017 00, 1 to 3 or more applications of the product per day for 1 month, 319 subjects

Vendrely V *et al.* An Emollient PLUS Balm is useful for the management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study. *Dermatol Ther (Heidelb)*. 2022 Mar;12(3):683-699.